RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0043-1776316
Diagnostic disclosure of Alzheimer's disease in Brazil: a national survey of specialized physicians
Revelação do diagnóstico da doença de Alzheimer no Brasil: prática corrente de médicos que atendem pacientes com demênciaAutoren
Abstract
Background: The diagnosis of Alzheimer's disease (AD) can bring financial and emotional consequences to patients and caregivers. Whether or not the diagnosis should be disclosed to patients is a matter of debate amongst physicians and can be influenced by culture and experience.
Objective: To investigate the current practice of physicians who attend and treat patients with dementia in Brazil regarding the disclosure of dementia diagnosis and compare the practice with what has been performed 15 years ago in the country.
Methods: Data were evaluated using an electronic questionnaire. The questions used to carry out this research were similar to the questions of the study carried out 15 years ago 9. The form was sent to the Brazilian Academy of Neurology, the Brazilian Association of Geriatrics and Gerontology, and the Brazilian Association of Psychiatry, which forwarded it to their members. Analyses were conducted through non-parametric statistical tests, with a post-hoc assessment.
Results: 397 physicians responded to the survey, of which 231 are neurologists, 124 geriatricians, 29 psychiatrists and 13 from other specialties. The mean age was 45.2 years. The majority (66.7%) of the physicians reveal the diagnosis of AD always or usually. The youngest group of neurologists were more likely to disclose the diagnosis than the oldest group with a significant difference between them. In comparison to the 2008 Brazilian study, the percentage of physicians who always or usually disclose the diagnosis has risen by 22%. On the other hand, 12.3% of the physicians rarely or never disclose the diagnosis, in comparison to 25,3% in 2008. The main reasons for not disclosing the diagnosis concern the patients' mental health.
Conclusion: Advances in dementia knowledge and biomarkers availability probably explain the increase in the rate of disclosure. The main challenge is to reconcile the autonomy of affected individuals, mental health issues after the diagnosis and the family member's opinion.
Resumo
Antecedentes: O diagnóstico da doença de Alzheimer (DA) pode trazer consequências financeiras e emocionais para pacientes e cuidadores. Revelar ou não o diagnóstico aos pacientes é uma questão de debate entre os médicos e pode ser influenciada pela cultura e experiência.
Objetivo: Investigar a prática atual dos médicos que atendem e tratam pacientes com demência no Brasil quanto à revelação do diagnóstico de demência e comparar a prática com a qual era feita há 15 anos no país.
Métodos: Os dados foram avaliados por meio de um questionário eletrônico. As perguntas usadas para realização dessa pesquisa foram similares às perguntas do estudo realizado há 15 anos 9. O formulário foi enviado à Academia Brasileira de Neurologia, à Associação Brasileira de Geriatria e Gerontologia, e à Associação Brasileira de Psiquiatria, as quais o encaminharam aos seus membros. As análises foram realizadas por meio de testes estatísticos não paramétricos, com avaliação post-hoc.
Resultados: 397 médicos responderam à pesquisa, sendo 231 neurologistas, 124 geriatras, 29 psiquiatras e 13 de outras especialidades. A média de idade foi de 45,2 anos (standard deviation-SD = 11.6 years). A maioria (66,7%) dos médicos revela o diagnóstico de DA sempre ou habitualmente. O grupo mais jovem de neurologistas foi mais propenso a revelar o diagnóstico do que o mais velho, com diferença significativa entre eles. Em comparação com o estudo brasileiro de 2008, o percentual de médicos que sempre ou usualmente revelam o diagnóstico aumentou em 22%. Em contrapartida, 12,3% dos médicos raramente ou nunca o divulgam, em comparação a 25,3% em 2008. Os principais motivos para não o revelar dizem respeito à saúde mental dos pacientes.
Conclusão: Avanços no conhecimento da demência e disponibilidade de biomarcadores provavelmente explicam o aumento na taxa de divulgação. O principal desafio é conciliar a autonomia dos indivíduos afetados, problemas de saúde mental após o diagnóstico e opinião do familiar.
Authors' Contributions
VSS: design of the study, was responsible for the collection, analysis of the data, statistical analysis and for the preparation of the manuscript and its review; SBG, LCC: design of the study and preparation of the manuscript; EPFR, LCS, MTB: manuscript's review; PC: conception and design of the study, while also contributing to the collection and analysis of the data and to preparation of the manuscript and its review.
Publikationsverlauf
Eingereicht: 22. Mai 2023
Angenommen: 20. August 2023
Artikel online veröffentlicht:
08. November 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Feter N, Leite JS. Is Brazil ready for the expected increase in dementia prevalence?. Cad Saude Publica 2021; 37 (06) e00056421 Doi: 10.1590/0102-311. Doi: ×00056421
- 2 GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7 (02) PubMed
- 3 Alzheimer's Disease International. Dementia statistics. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ . Acesso em 03/11/2022
- 4 United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects. 2022. : Summary of Results. eISBN: 9789210014380
- 5 Carvalho JAlberto Magno de, Rodríguez-Wong LL. A transição da estrutura etária da população brasileira na primeira metade do século XXI. Cadernos de Saúde Pública [online]. 2008; 24 (03) ) [Acessado 1 Novembro 2022], pp. 597-605 . Epub 05 Mar 2008. ISSN 1678-4464 PubMed
- 6 Nichols E, Szoeke C, Vollset S. et al; GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (01) 88-106
- 7 Sarafis P, Tsounis A, Malliarou M, Lahana E. Disclosing the truth: a dilemma between instilling hope and respecting patient autonomy in everyday clinical practice. Glob J Health Sci 2013; 6 (02) 128-137
- 8 Pagliosa FL, Da Ros MA. O Relatório Flexner: Para o Bem e Para o Mal. Rev Bras Educ Med 2008; 32 (04) 492-499
- 9 Raicher I, Shimizu MM, Takahashi DY, Nitrini R, Caramelli P. Alzheimer's disease diagnosis disclosure in Brazil: a survey of specialized physicians' current practice and attitudes. Int Psychogeriatr 2008; 20 (03) 471-481
- 10 Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychol Aging 2009; 24 (02) 373-384
- 11 Gutzmann H, Qazi A. Depression associated with dementia. Z Gerontol Geriatr 2015; 48 (04) 305-311
- 12 Klyucherev TO, Olszewski P, Shalimova AA. et al. Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener 2022; 11 (01) 25
- 13 Schilling LP, Balthazar MLF, Radanovic M. et al. Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol 2022; 16 (3, Suppl 1) 25-39